阿昔替尼联合帕博利珠单抗治疗晚期肾细胞癌:I期试验长期疗效与安全性
中位随访42.7个月时,中位OS未达到,4年生存概率66.8%,中位PFS 23.5个月,ORR 73.1%,中位DoR 22.1个月,未发现新的安全性信号。
要点
- 中位随访42.7个月,中位OS未达到,4年生存概率66.8%。
- 中位PFS 23.5个月,ORR 73.1%,其中5例完全缓解。
- 3/4级不良事件发生率73.1%,38.5%因不良事件停药。
核心结论
- 在晚期肾细胞癌患者中,阿昔替尼联合帕博利珠单抗经过约4年随访持续显示临床获益,且未出现新的安全性信号。
主要发现
- 中位随访42.7个月(95%CI 41.1-44.1),中位OS未达到,38例(73.1%)患者存活。
- 4年生存概率为66.8%(95%CI 49.1-79.5)。
- 总体人群中位PFS为23.5个月(95%CI 15.4-30.4)。
- ORR为73.1%,其中5例完全缓解;中位DoR为22.1个月(95%CI 15.1-34.5)。
- 3/4级不良事件发生于38例(73.1%)患者,20例(38.5%)因不良事件停药:17例(32.7%)停阿昔替尼,13例(25.0%)停帕博利珠单抗,10例(19.2%)停两种药物。
关键数值与推荐
- 常见不良事件包括腹泻(84.6%)、乏力(80.8%)、高血压(53.8%)、咳嗽(48.1%)和发声困难(48.1%)。
- 未报告新的不良事件术语,无治疗相关死亡。
临床怎么用
- 对于初治晚期肾细胞癌患者,阿昔替尼联合帕博利珠单抗可作为一项具有长期生存获益的治疗选择,但需注意监测3/4级不良事件及因毒性停药的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Axitinib plus pembrolizumab showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) versus sunitinib in a randomised phase III trial in patients with advanced renal-cell carcinoma (RCC). We report long-term efficacy and safety of the axitinib/pembrolizumab from the phase I trial (NCT02133742), after 46-55 months from study initiation (data cut-off date, 23rd July 2019). METHODS: Fifty-two treatment-naïve patients with advanced RCC were treated with oral axitinib 5 mg twice daily and intravenous pembrolizumab 2 mg/kg every 3 weeks. PFS, duration of response (DoR) and OS were summarised using the Kaplan-Meier method. RESULTS: At a median follow-up of 42.7 months (95% confidence interval [CI]: 41.1-44.1), median OS was not reached; 38 (73.1%) patients were alive. The probability of being alive at 4 years was 66.8% (95% CI: 49.1-79.5). Median PFS in the overall population was 23.5 months (95% CI: 15.4-30.4). ORR was 73.1%; five patients had complete response. Median DoR was 22.1 months (95% CI: 15.1-34.5). Grade III/IV adverse events (AEs) were reported in 38 (73.1%) patients and 20 (38.5%) discontinued treatment because of AEs: 17 (32.7%) discontinued axitinib, 13 (25.0%) discontinued pembrolizumab, and 10 (19.2%) discontinued both drugs. Common AEs included diarrhoea (84.6%), fatigue (80.8%), hypertension (53.8%), cough (48.1%) and dysphonia (48.1%). There were no new AE terms reported and no treatment-related deaths. CONCLUSIONS: In patients with advanced RCC with ~4 years of follow-up, combination axitinib/pembrolizumab continued to demonstrate clinical benefit, with no new safety signals.
引用
- Atkins MB, Plimack ER, Puzanov I, et al. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. Eur J Cancer. 2021. PMID: 33412465. doi:10.1016/j.ejca.2020.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。